| INTRODUCTION
Despite advances in the delivery and quality of supportive care, judicious use of antimicrobial therapy, and global epidemiologic shifts, sepsis remains a leading cause of morbidity and mortality worldwide, leading to an estimated 5 million deaths annually. 1 Sepsis is an infection-induced systemic inflammatory response syndrome that typically progresses to organ hypoperfusion and death within hours to days when left untreated. 2 The increasing focus on the role of the host reflected in the definition of sepsis, rather than the pathogen itself, has been a paradigm shift emphasized by society guidelines in recent years 2 and highlights an unmet clinical need to explore novel methods targeting the unique pathobiology of this syndrome.
Physiologic pathways involved in the dysregulated host response in sepsis include the inflammatory cascade, complement system, and the coagulation system. While often considered isolated entities, these systems are in fact intimately linked, with perturbations in one affecting the others. These relationships can be collectively referred to as immunothrombosis and suggest a role for coagulation as a form of innate immune defense. Purported mechanisms of coagulation being protective against disseminated infection include trapping of pathogens and leukocytes within fibrin thrombi, as well as prevention of pathogens exiting the vascular space into the tissues. 3 At its most extreme, progression of this immunothrombosis mechanism can lead to disseminated intravascular coagulation (DIC), characterized by systemic activation and consumption of coagulation factors, platelets, and fibrinogen, leading to both widespread thrombosis and bleeding, and contributing substantially to the morbidity of sepsis ( Figure 1 ).
| HISTORICAL ATTEMPTS AT TARGETING IMMUNOTHROMBOSIS IN SEPSIS
Historical attempts to attenuate the activation of coagulation in patients with sepsis have been met with equivocal benefit and potential harm, most notably with the use of activated protein C (APC; drotrecogin alfa, Xigris). Drotrecogin alfa was theorized to confer a benefit in sepsis by repleting a natural anticoagulant (APC) that was known to be decreased in septic patients, as well as augmenting its cytoprotective effects via protease-activated receptor (PAR)-1 signaling. 4 Early-phase human trials of APC in sepsis were compelling due to significant reductions in inflammatory cytokine levels as well as statistically significantly improved mortality compared with placebo. 5 A subsequent large, phase 3, placebo-controlled trial of drotrecogin alfa in sepsis, however, failed to show this same mortality benefit after both acute and F I G U R E 1 Bacteria-induced contact activation leading to immunothrombosis and DIC. The coagulation factor XII (FXII) is activated by live bacteria and bacterial wall-derived pathogen-associated molecular patterns (PAMPS), such as lipopolysaccharides (LPS) for gramnegative or peptidoglycan (PGN) for gram-positive bacteria or bacteria-produced long-chain polyphosphates (lc-PolyP). Activation of FXII leads to thrombin generation, platelet activation, and fibrin formation, which in concert trap and contain pathogens. Activated platelets promote neutrophils to release their nuclear contents to form extracellular traps (netosis) as part of the routes of pathogen clearance; NETs are also potent platelet activators and cytotoxic to the host cells. Histones and double-stranded DNA (dsDNA) act as damage-associated pattern molecules (DAMPs) that together with platelet-derived short-chain polyphosphates (sc-polyPs) contribute to contact activation via direct and indirect mechanisms. Failing the redundant pathways of pathogen clearance offered by the immune and coagulation systems, immunothrombosis can result in widespread microvascular thrombosis termed disseminated intravascular coagulation (DIC) followed by consumptive coagulopathy and bleeding. Thrombosis within the microvasculature of vital organs leads to ischemia, hypoperfusion, and oxidative stress, thus impairing organ function and leading to multiple organ failure (MOF). When more than two organs fail, death is the most likely outcome long-term follow-up, and the drug was subsequently removed from the market. 6 Drotrecogin alfa also led to a significantly higher incidence of bleeding, including some instances of major hemorrhage, than placebo. 7 Data on the use of heparin products as adjunctive therapy for sepsis, despite benefits reported in several meta-analyses, must be interpreted with caution due to these analyses' frequent inclusion of nonrandomized studies, variable definitions of sepsis, and the concomitant use of other investigational agents (APC, antithrombin, and others). 3 In addition, bleeding remains a persistent, unwanted side effect of most traditional anticoagulants used in this setting. Given that no anticoagulant has ever shown a convincing benefit in sepsis, their routine use is not currently recommended in septic patients without another indication for anticoagulation. Thus, the contact system represents a specific node linking the inflammatory and coagulopathic responses that contribute to the pathogenesis of sepsis, and represents a biologically plausible potential target upon which to focus research on novel therapeutics.
A growing body of literature has examined the specific physiologic roles of contact factors, epidemiologic data on contact factor deficiencies in humans, and numerous animal models of both genetic and drug-induced factor deficiencies. The general conclusion of this work is that that the contact system has a limited role in hemostasis but can generate and amplify pathologic thrombosis and inflammation, and potentially could be safely inhibited to confer benefits in various disease states.
The CAS is activated upon blood exposure to an increasing number of recognized substances, including negatively charged artificial surfaces, various infectious pathogens, long-chain polyphosphates (polyPs), and cell-free DNA/RNA. In sepsis in particular, CAS activation seems to be triggered by contact with negatively charged surfaces, including platelet-derived polyP and bacterial cell components such as peptidoglycans, teichoic acid, and lipopolysaccharide. 9 Upon exposure to an activating surface, FXII changes conformation to become the serine protease FXIIa. This enzyme activates PK to form kallikrein (PKa), which, via reciprocal activation of FXIIa, rapidly increases the serum concentration of both enzymes. 15 This work suggests that bacterial components, including long-chain polyP, promote platelet activation in an FXII-dependent manner in flowing blood, which may contribute to sepsis-associated thrombotic processes, consumptive coagulopathy, and thrombocytopenia.
Contact activation affects common surface-activated coagulation assays, including the activated partial thromboplastin time (aPTT) and activated clotting time, but has not been found to correlate meaningfully with true hemostatic potential. Indeed, the activation of FXI by FXIIa is considered dispensable for normal hemostasis but does play a prominent role in thrombin generation in pathologic settings. 17 This has been shown clinically, as FXI deficiency is associated with a mild bleeding diathesis typically only in the face of sufficient traumatic or surgical challenge despite markedly elevated aPTT values, unlike the frequently spontaneous hemorrhage seen in FVIII and FIX deficiencies. 18 Even more compelling is the apparent lack of abnormal bleeding of any type seen in congenital FXII deficiency, 19 though these individuals have rarely been encountered. The Ashkenazi Jewish population has a relatively high rate of congenital FXI deficiency, and a large, retrospective cohort study of FXI-deficient patients in Israel demonstrated significantly reduced rates of both venous and arterial thrombotic events over a decade of follow-up. 20 Epidemiologic data on the effect of FXII deficiency on thrombosis are scarce and remain inconclusive. 21 Certain animal populations with congenital FXI deficiency, including Holstein cattle, may have an increased susceptibility to pulmonary infection, but the contact proteins do not seem to play a significant role in innate immunity in humans. 22 The various data describing the ways in which the CAS plays a multimodal role in organisms' responses to infection are outlined through the remainder of this text and in Table 1 .
These data make selective inhibition of the CAS an attractive 
| MURINE STUDIES
The catalytic role of FXI in immunothrombosis suggests that its absence may lead to a less severe host inflammatory response and improved morbidity and mortality in the setting of systemic infection.
Evidence from several animal models supports this hypothesis.
When challenged with high doses of intraperitoneal Listeria monocytogenes, FXI knockout mice were found to develop a less severe coagulopathy and lower serum cytokine levels than their wild-type (WT) counterparts. 23 FXI knockout mice likewise displayed significantly higher serum fibrinogen levels, platelet counts, and reduced thrombin-antithrombin complex (TAT) levels after inoculation with high-dose L. monocytogenes as compared to controls.
Plasma markers of inflammation, including interleukin (IL)-6 and hepatic mRNA encoding IL-6 and IL-10, were detected at significantly lower levels in the FXI-deficient animals. The attenuated inflammation in the FXI-deficient mice resulted in measurable improvements in end-organ outcomes as well: whereas WT mice were found on histologic analysis to have large areas of hepatic necrosis, FXI-deficient mice had relatively scant necrosis and less inflammatory cell infiltration in the liver parenchyma. Finally, FXI-deficient mice demonstrated significantly improved survival: while only 30% of WT mice survived to day 10 after inoculation, 67% of FXI-deficient mice were alive on day 20.
24
The protective effect of FXI deficiency appears to extend to polymicrobial infections as well. After inducing peritoneal sepsis via cecal ligation and puncture (CLP), FXI-deficient mice experienced a substantially smaller decrease in platelet count than WT mice, suggesting a milder consumptive coagulopathy. 23 Prothrombin time, a marker of plasma clotting factor levels, increased markedly in WT mice after CLP but remained unchanged in FXI-deficient animals, and correspondingly TAT levels were reduced in FXI-deficient
TA B L E 1 Effects of FXI inhibition on coagulation and inflammation

Processes Findings
Coagulopathy
In in vitro studies, FXI was found to be directly activated by thrombin independent of FXII.
47,48
In a human in vivo model of low-grade endotoximea, thrombin generation and FXI activation were detected in the absence of FXII activation. 37 In a perforation-induced peritoneal sepsis model, mice anticoagulated with a selective antibody (14E11) that inhibited FXI activation by FXIIa led to suppression of systemic thrombin-antithrombin complex formation.
26
In a cecal puncture-and ligation-induced sepsis model, FXI-deficient mice exhibited lower FXII activation in the presence of microbial molecules (eg, polyphosphate), revealing the role of activated FXIa in feedback activation of FXII in the presence of polyanions. 25 In human blood studies ex vivo and in primates in vivo, presence of microbial molecules (eg polyphosphates, potentiated thrombin generation and fibrin formation in FXII-FXI axis-dependent manner. 15 
Platelet consumption
In a perforation-induced peritoneal sepsis model, mice anticoagulated with a selective antibody (14E11) that inhibited FXI activation by FXIIa led to reduced platelet consumption in the circulation and deposition in the blood vessels.
26
In human blood studies ex vivo and in primates in vivo, FXI potentiated thrombin generation at a local site of thrombus formation and led to platelet microaggregate formation and single platelet consumption in flowing blood distal to the local site of thrombus formation.
15,16
Cytokine production and inflammation
In a cecal puncture-induced sepsis model, FXI-deficient mice had a survival advantage with significant smaller increases in plasma levels of TNF-α and IL-10 and delayed IL-1β and IL-6 responses.
23,25
In a cecal puncture-induced sepsis model, FXI-deficient mice expressed reduced serum levels of an acute phase inflammatory protein, amyloid P.
25,26
In a perforation-induced peritoneal sepsis model, mice anticoagulated with a selective antibody (14E11) that inhibited FXI activation by FXIIa led to suppression of systemic IL-6 and TNF-α levels. 25 In nonhuman primate studies, inhibition of FXII-and FXII-mediated activation of FXI have both been shown to blunt the cytokine response and improve measurable physiologic outcomes after inoculation with live or heat-inactivated bacterium.
15,34
Neutrophil function Coagulation FXI was found to immunolocalize with human neutrophil membrane bound by kininogen.
49
In a cecal puncture-induced sepsis model, FXI-deficient mice had decreased lymphocyte accumulation in infected tissues. 23 In in vitro assays, purified polymorphonuclear leukocytes exposed to activated FXIa exhibited less chemokine-induced chemotaxis and calcium release.
In Streptococcus pneumoniae and Klebsiella pneumoniae models, FXI-deficient mice had lower levels of phagocytosis. Survival at 7 days was also significantly higher in the FXI knockout mice than WT in this follow-on study (39% vs 6%).
25
Antibody-mediated FXI inhibition has also been applied to the CLP polymicrobial sepsis model with similarly favorable results. which has led to further evaluation of the role of FXI and FXII inhibition in nonhuman primate models.
| NONHUMAN PRIMATE MODELS
Original work by Pixley et al 32 and Jansen et al 33 in the 1990s
showed the beneficial effects of FXII inhibition in a baboon model of E. coli sepsis. 32 Wild-type baboons showed a significant decrease in HK and increase in alpha-2 macroglobulin-kallikrein complexes in the blood compared to baboons given a dose of a FXII-inhibiting antibody (C6B7). Most impressively, terminal hypotension was attenuated in the group that received C6B7; while both control baboons and those treated with the FXII inhibitor C6B7 developed initial hypotension, the control group subsequently developed irreversible lethal hypotension, while shock was reversible in those with inhibited FXII. These findings suggested that the upstream role of FXII in regulating bradykinin may participate in the pathologic shock that develops in severe sepsis. A similar study also showed that pretreatment with the FXII inhibitor C6B7 before E. coli inoculation led to reduced complement activation, neutrophil degranulation, and levels of tissue plasminogen activator and IL-6 compared to untreated baboons. 
34
Inhibition of FXI with 3G3 resulted in a marked blunting of the cytokine storm associated with bacteremia and sepsis. Plasma levels of IL-6, IL-8, monocyte chemoattractant protein-1, granulocyte-macrophage colony-stimulating factor, and IL-1β were lower in treated animals than in controls, reflecting reduced cytokine production. Treated animals also displayed decreased complement cascade activation reflected by lower levels of circulating C3b and C5b-9 terminal complement complex. 34 How FXI activation contributes to cytokine production and complement activation is not 
| HUMAN DATA
Minnema and colleagues performed an informative experiment in which they infused 8 healthy volunteers with a low dose of endotoxin in an attempt to measure contact pathway activation. They found a significant increase in FXIa, peaking at 1 and 2 hours after endotoxin infusion, followed by a gradual increase in FXIa-FXIa inhibitor complexes. Thrombin generation peaked at 3 to 4 hours after infusion, and in contrast, markers of activation of prekallikrein and FXII remained undetectable. 37 While data specific to sepsis are limited, several studies have shown increased contact pathway activation using blood samples from septic patients. Using assays measuring FXIIa-C1-inhibitor, kallikrein-C1-inhibitor, and FXIa-inhibitor complexes, several studies have shown FXII activation and kallikrein formation in both adult and pediatric patients with sepsis. [38] [39] [40] [41] Likewise, recent studies have suggested that the reduced form of coagulation factor XI is associated with worse outcomes and coagulopathy in septic patients.
42
While these data suggest that the CAS contributes to the pathology of sepsis in humans, further study is needed before any major conclusions are drawn to determine if targeting this pathway could offer a meaningful benefit to septic patients. As multiple novel contact pathway inhibitors enter clinical testing, additional clinical investigations may begin to address this question.
43-45
| LIMITATIONS AND REMAINING QUESTIONS
The evidence supporting a positive effect of contact pathway inhibition on outcomes in sepsis is noteworthy mechanistically and in preclinical animal models. However, the therapeutic pos- The innate heterogeneity of sepsis is a major barrier to identi- 
| CONCLUSIONS
The role of the contact activation system in catalyzing down- 
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